Bill Carlezon, PhD, chief of McLean’s Jerry and Phyllis Rappaport Center of Excellence in Basic Neuroscience Research and director of the Behavioral Genetics Laboratory, has agreed to continue in his role as editor in chief of Neuropsychopharmacology, the official journal of the American College of Neuropsychopharmacology, until December 31, 2022.
In addition to his efforts to attract and publish cutting-edge clinical and preclinical research, Carlezon is recognized for updating the journal to optimize alignment with current and future trends in publishing, including use of social media to make content broadly accessible to both scientists and non-scientists.
Under his leadership, Neuropsychopharmacology boasted an impact factor—a measure of how frequently a journal’s articles are cited—of 6.403 in 2016 and currently ranks 12th among 142 psychiatry journals, 14th among 256 pharmacology and pharmacy journals, and 21st among 258 neuroscience journals.
Carlezon’s push to reach new audiences through digital outreach has resulted in the journal seeing its online readership spike in 2016 with 2,232,725 page views, about 1.35 million site visits, and over 1.7 million article views.
The site averaged nearly 4.7 thousand visits per day, 68% of the page views were from outside the United States, and more than 75,000 individuals registered for the journal’s electronic table of contents alerts.
Carlezon is a professor of psychiatry at Harvard Medical School and has received several awards for his research, including an Independent Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Presidential Early Career Award for Scientists and Engineers (PECASE) from George W. Bush, and the Jacob P. Waletzky Award for Innovative Research in Drug Addiction and Alcoholism from the Society for Neuroscience (SfN).
He is also a member of the Scientific Advisory Board for Autism Speaks and winner of the 2016 Anne M. Cataldo Excellence in Mentoring Award.